AR030037A1 - Sistema de administracion de anticonceptivo transdermico mejorado y el uso de una capa de soporte y una matriz polimerica para la fabricacion de un sistema de administracion de anticonceptivo - Google Patents
Sistema de administracion de anticonceptivo transdermico mejorado y el uso de una capa de soporte y una matriz polimerica para la fabricacion de un sistema de administracion de anticonceptivoInfo
- Publication number
- AR030037A1 AR030037A1 ARP000106197A ARP000106197A AR030037A1 AR 030037 A1 AR030037 A1 AR 030037A1 AR P000106197 A ARP000106197 A AR P000106197A AR P000106197 A ARP000106197 A AR P000106197A AR 030037 A1 AR030037 A1 AR 030037A1
- Authority
- AR
- Argentina
- Prior art keywords
- fertility
- hormones
- control
- estrogen
- administration system
- Prior art date
Links
- 230000035558 fertility Effects 0.000 abstract 7
- 229940088597 hormone Drugs 0.000 abstract 7
- 239000005556 hormone Substances 0.000 abstract 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 abstract 4
- 229940011871 estrogen Drugs 0.000 abstract 4
- 239000000262 estrogen Substances 0.000 abstract 4
- 239000000583 progesterone congener Substances 0.000 abstract 4
- 235000014655 lactic acid Nutrition 0.000 abstract 3
- 239000004310 lactic acid Substances 0.000 abstract 3
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 abstract 2
- 239000000853 adhesive Substances 0.000 abstract 2
- 230000001070 adhesive effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003433 contraceptive agent Substances 0.000 abstract 2
- 230000002254 contraceptive effect Effects 0.000 abstract 2
- -1 fatty alcohol ester Chemical class 0.000 abstract 2
- 239000003906 humectant Substances 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000004014 plasticizer Substances 0.000 abstract 2
- 231100000245 skin permeability Toxicity 0.000 abstract 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 1
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 abstract 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960002568 ethinylestradiol Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229960004400 levonorgestrel Drugs 0.000 abstract 1
- 229960002826 levonorgestrel and ethinylestradiol Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000027758 ovulation cycle Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Un sistema de administracion de anticonceptivos transdérmico mejorado del tipo que comprende una capa de soporte que es sustancialmente impermeable a las hormonas de estrogeno y progestina que controlan la fertilidad, para ser administrado transdérmicamente y una matriz polimérica adhesiva fija a la capa de soporte, donde la mejora comprende ingredientes del soporte que consisten, en una base de porcentaje en peso, de aproximadamente 0 a aproximadamente 10% de humectante/plastificante, de aproximadamente 10 a aproximadamente 60% de una combinacion de agentes que mejoran la permeacion a la piel, que es una mezcla que comprende a sulfoxido de dimetilo, un éster de alcohol graso de C8-20 de ácido láctico, un éster de alquilo inferior C1-4 de ácido láctico y ácido cáprico presentes en una porcion que fluctua de aproximadamente 6:1:1:0.8 y una cantidad efectiva para controlar la fertilidad de hormonas de estrogeno y progestina en donde tales hormonas proporcionan por lo menos dosis diarias efectivas de 20 mcg/día para levonorgestrel y 10 a 50 mcg/día para etinil estradiol. Uso de a) una capa de soporte que es sustancialmente impermeable a las hormonas de estrogeno y progestina que controlan la fertilidad a ser administrada transdermicamente; (b) una matriz polimérica adhesiva fija a la capa de soporte que comprende, en una base de porcentaje en peso, de aproximadamente 0% a aproximadamente 10% de humectante/plastificante, de aproximadamente 30 a aproximadamente 60% de una combinacion de agentes que mejoran la permeacion a la piel que es una mezcla que consiste de sulfoxido de dimetilo, un éster de ácido láctico de alcohol graso C8-20, un alquil éster inferior (C1-4) de ácido láctico y ácido cáprico presente en una proporcion de aproximadamente 2.0:1:1:0.8 a aproximadamente 6:1:1:0.8 respectivamente y una cantidad efectiva de hormonas de estrogeno y progestina que controlan la fertilidad, en donde tales hormonas proporcionan por lo menos mínimas dosis diarias efectivas de tales hormonas para efectuar el control de la fertilidad, para proporcionar por lo menos las mínimas cantidades de dosis efectivas de levonorgestrel y etinil estradiol por aproximadamente las primeras tres semanas de ciclo menstrual por ciclos menstruales sucesivos por un período que se extiende hasta donde se desea el control de la fertilidad, que es para la fabricacion de un sistema de administracion de anticonceptivo transdérmico para controlar la fertilidad mediante la aplicacion a la piel de un sujeto que desea tal tratamiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16753599P | 1999-11-24 | 1999-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030037A1 true AR030037A1 (es) | 2003-08-13 |
Family
ID=22607771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000106197A AR030037A1 (es) | 1999-11-24 | 2000-11-23 | Sistema de administracion de anticonceptivo transdermico mejorado y el uso de una capa de soporte y una matriz polimerica para la fabricacion de un sistema de administracion de anticonceptivo |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1242012B1 (es) |
| JP (2) | JP4841781B2 (es) |
| KR (1) | KR100758757B1 (es) |
| CN (1) | CN1399533A (es) |
| AR (1) | AR030037A1 (es) |
| AT (1) | ATE453374T1 (es) |
| AU (2) | AU784196B2 (es) |
| BR (1) | BR0015802B1 (es) |
| CA (1) | CA2391430C (es) |
| CY (1) | CY1110615T1 (es) |
| DE (1) | DE60043621D1 (es) |
| DK (1) | DK1242012T3 (es) |
| ES (1) | ES2338860T3 (es) |
| IL (1) | IL149655A0 (es) |
| MX (1) | MXPA02005224A (es) |
| NO (1) | NO331218B1 (es) |
| NZ (1) | NZ518723A (es) |
| PT (1) | PT1242012E (es) |
| TW (1) | TWI253350B (es) |
| WO (1) | WO2001037770A1 (es) |
| ZA (1) | ZA200203525B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045145B1 (en) | 1999-11-24 | 2006-05-16 | Agile Therapeutics, Inc. | Transdermal contraceptive delivery system and process |
| US7384650B2 (en) * | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
| DE10159120B4 (de) * | 2001-12-01 | 2006-08-17 | Lts Lohmann Therapie-Systeme Ag | Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung |
| SI1594483T1 (sl) | 2003-02-21 | 2006-12-31 | Schering Ag | UV-stabilni transdermalni terapevtski obliz |
| EP1624848A4 (en) * | 2003-05-02 | 2009-02-25 | Duramed Pharmaceuticals Inc | METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE |
| ES2626784T3 (es) * | 2003-10-28 | 2017-07-26 | Noven Pharmaceuticals, Inc. | Dispositivo de administración transdérmica de fármacos |
| US8668925B2 (en) | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| UA89766C2 (en) | 2003-12-12 | 2010-03-10 | Байер Шеринг Фарма Акциенгезельшафт | Transdermal delivery system of gestodene |
| US9205062B2 (en) | 2004-03-09 | 2015-12-08 | Mylan Pharmaceuticals, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
| US20050202073A1 (en) | 2004-03-09 | 2005-09-15 | Mylan Technologies, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
| CN1313084C (zh) * | 2004-11-05 | 2007-05-02 | 郑会义 | 一种透皮避孕药传送体系及制备方法 |
| CN1318032C (zh) * | 2005-01-24 | 2007-05-30 | 浙江大学 | 炔雌醇透皮吸收贴片 |
| US8962013B2 (en) | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
| WO2008088593A2 (en) * | 2006-09-27 | 2008-07-24 | Surmodics, Inc. | Additives and methods for enhancing active agent elution kinetics |
| GB0809905D0 (en) * | 2008-06-02 | 2008-07-09 | Secr Defence | A Transdermal drug delivery device |
| CN102665683A (zh) | 2009-10-12 | 2012-09-12 | 丽卡实验有限公司 | 紧急避孕药 |
| AU2011238710B2 (en) | 2010-03-28 | 2015-08-20 | Evestra, Inc. | Intravaginal drug delivery device |
| DE102010040299A1 (de) | 2010-09-06 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner) |
| US10028858B2 (en) | 2011-07-11 | 2018-07-24 | Medicines360 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor |
| EP2773333B1 (en) * | 2011-11-04 | 2019-10-02 | Agile Therapeutics, Inc. | Dermal delivery compositions and methods |
| CA2894696A1 (en) | 2012-12-21 | 2014-06-26 | Teikoku Pharma Usa, Inc. | Compositions and methods for transdermal delivery of hormones and other medicinal agents |
| TW201431554A (zh) | 2012-12-28 | 2014-08-16 | Noven Pharma | 左炔諾孕酮（ｌｅｖｏｎｏｒｇｅｓｔｒｅｌ）及乙烯雌二醇之經皮藥物遞送系統 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3632740A (en) * | 1968-06-13 | 1972-01-04 | Johnson & Johnson | Topical device for the therapeutic management of dermatological lesions with steroids |
| JPS5843368B2 (ja) * | 1980-10-30 | 1983-09-27 | 日東電工株式会社 | 消炎鎮痛貼付剤 |
| US5023084A (en) * | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| AU679793B2 (en) * | 1993-09-29 | 1997-07-10 | Alza Corporation | Monoglyceride/lactate ester permeation enhancer |
| ES2180658T3 (es) * | 1994-11-17 | 2003-02-16 | Toray Industries | Preparado para absorcion percutanea. |
| PL181582B1 (pl) * | 1995-06-07 | 2001-08-31 | Ortho Mcneil Pharm Inc | Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL |
| US5762956A (en) | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
-
2000
- 2000-11-22 AT AT00980651T patent/ATE453374T1/de active
- 2000-11-22 JP JP2001539387A patent/JP4841781B2/ja not_active Expired - Fee Related
- 2000-11-22 CN CN00816271A patent/CN1399533A/zh active Pending
- 2000-11-22 DK DK00980651.4T patent/DK1242012T3/da active
- 2000-11-22 AU AU17883/01A patent/AU784196B2/en not_active Ceased
- 2000-11-22 EP EP00980651A patent/EP1242012B1/en not_active Expired - Lifetime
- 2000-11-22 ES ES00980651T patent/ES2338860T3/es not_active Expired - Lifetime
- 2000-11-22 WO PCT/US2000/032043 patent/WO2001037770A1/en active IP Right Grant
- 2000-11-22 DE DE60043621T patent/DE60043621D1/de not_active Expired - Lifetime
- 2000-11-22 CA CA002391430A patent/CA2391430C/en not_active Expired - Fee Related
- 2000-11-22 PT PT00980651T patent/PT1242012E/pt unknown
- 2000-11-22 KR KR1020027006580A patent/KR100758757B1/ko active IP Right Grant
- 2000-11-22 BR BRPI0015802-0B1A patent/BR0015802B1/pt not_active IP Right Cessation
- 2000-11-22 NZ NZ518723A patent/NZ518723A/en not_active IP Right Cessation
- 2000-11-22 MX MXPA02005224A patent/MXPA02005224A/es active IP Right Grant
- 2000-11-22 IL IL14965500A patent/IL149655A0/xx not_active IP Right Cessation
- 2000-11-23 AR ARP000106197A patent/AR030037A1/es not_active Application Discontinuation
-
2001
- 2001-01-03 TW TW089124926A patent/TWI253350B/zh not_active IP Right Cessation
-
2002
- 2002-05-03 ZA ZA200203525A patent/ZA200203525B/xx unknown
- 2002-05-22 NO NO20022420A patent/NO331218B1/no not_active IP Right Cessation
-
2006
- 2006-05-09 AU AU2006201918A patent/AU2006201918B2/en not_active Ceased
-
2010
- 2010-03-22 CY CY20101100276T patent/CY1110615T1/el unknown
-
2011
- 2011-07-25 JP JP2011161744A patent/JP2011231125A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU1788301A (en) | 2001-06-04 |
| ES2338860T3 (es) | 2010-05-13 |
| AU2006201918A1 (en) | 2006-06-01 |
| BR0015802A (pt) | 2003-06-24 |
| NO20022420L (no) | 2002-07-18 |
| KR20020072280A (ko) | 2002-09-14 |
| CA2391430C (en) | 2009-10-06 |
| CY1110615T1 (el) | 2015-04-29 |
| CA2391430A1 (en) | 2001-05-31 |
| AU2006201918B2 (en) | 2009-07-30 |
| KR100758757B1 (ko) | 2007-09-14 |
| PT1242012E (pt) | 2010-03-31 |
| CN1399533A (zh) | 2003-02-26 |
| JP4841781B2 (ja) | 2011-12-21 |
| EP1242012A4 (en) | 2006-05-31 |
| JP2011231125A (ja) | 2011-11-17 |
| NZ518723A (en) | 2004-04-30 |
| MXPA02005224A (es) | 2003-09-25 |
| ZA200203525B (en) | 2003-07-18 |
| NO20022420D0 (no) | 2002-05-22 |
| IL149655A0 (en) | 2002-11-10 |
| AU784196B2 (en) | 2006-02-23 |
| DK1242012T3 (da) | 2010-04-26 |
| EP1242012A1 (en) | 2002-09-25 |
| NO331218B1 (no) | 2011-11-07 |
| ATE453374T1 (de) | 2010-01-15 |
| JP2003533434A (ja) | 2003-11-11 |
| EP1242012B1 (en) | 2009-12-30 |
| TWI253350B (en) | 2006-04-21 |
| WO2001037770A1 (en) | 2001-05-31 |
| DE60043621D1 (de) | 2010-02-11 |
| BR0015802B1 (pt) | 2014-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030037A1 (es) | Sistema de administracion de anticonceptivo transdermico mejorado y el uso de una capa de soporte y una matriz polimerica para la fabricacion de un sistema de administracion de anticonceptivo | |
| KR100392435B1 (ko) | 성스테로이드를함유하는경피치료시스템 | |
| RU2176499C2 (ru) | Композиция для чрескожного введения стероидных лекарственных средств и содержащий ее препарат | |
| US5453279A (en) | Enhancing transdermal absorption compositions; transdermal dosage form; and process | |
| KR100561255B1 (ko) | 호르몬 방출용 트랜스더멀 치료 시스템 | |
| ITMI961152A1 (it) | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele | |
| CZ291656B6 (cs) | Transdermální terapeutický systém ve formě náplasti obsahující estradiol a způsob jeho výroby | |
| JP2014051507A (ja) | 避妊及びホルモン補充のためのノルエルゲストロミンを含む経皮治療システム | |
| ATE307569T1 (de) | Gelierbare pharmazeutische zusammensetzungen | |
| CN104936582B (zh) | 用于激素和其他药剂的经皮传送的组合物和方法 | |
| CA2169164A1 (en) | Low flux transdermal potent drug delivery system | |
| KR880701114A (ko) | 에스트라디올 및 기타 에스트로겐성 스테로이드용 경피 흡수 투여단위 및 그 투여방법 | |
| JP2009512658A5 (es) | ||
| PT95245B (pt) | Sistema de matriz solida para a libertacao transdermica de farmacos | |
| WO2007124250A2 (en) | Methods of treating hot flashes with formulations for transdermal or transmucosal application | |
| CN102858372A (zh) | 皮肤刺激抑制剂和经皮吸收制剂 | |
| JPH08500584A (ja) | ３−ケト−デソゲストレルを含有する経皮適用剤 | |
| AU2007317629A1 (en) | Transdermal delivery of ketoprofen polar derivatives | |
| JP2003533434A5 (es) | ||
| JPH08165251A (ja) | 溶解剤および該溶解剤を含有する外用製剤 | |
| CN101700246A (zh) | 复合避孕组合物以及含有该组合物的避孕透皮贴剂及制法 | |
| CZ284034B6 (cs) | Lanolinové deriváty jako látky podporující penetraci | |
| CN101843603A (zh) | 无需渗透促进剂的激素透皮传递 | |
| TWI343259B (en) | Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients | |
| CN1913878B (zh) | 无需渗透促进剂的激素透皮传递 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |